This proposal is to establish the Resource Facility for Population Kinetics (RFPK). The purpose of RFPK will be to promote the application of computer modeling in biomedical research focusing on compartmental population kinetics. Population kinetics in the methodology used to quantify inter-subject variability in kinetic studies. It is widely used in pharmacokinetic studies since it is the key to the understanding of how drugs behave in humans and animals. In metabolic (e.g. tracer) kinetic studies, it is used to identify those parameters in a model which change when comparing two populations. A growing number of researchers are recognizing the importance of software tools in this area and the need for individuals with the expertise to develop and apply them. RFPK will provide that expertise as part of fulfilling its goals which are: (1) the development and application of modeling technology to biomedical problems, 92) the development of general purpose algorithms for population kinetics, and making these algorithms easy to use through the development of graphical user interfaces for compartmental models, (3) supporting collaborative projects which help in the design and application of the software tools, (4) providing service and training to our user community, and (5) disseminating our technology, expertise and accomplishments. The proposed software tools will be designed in a modularized fashion. Some modules will be made available to other software developers thus extending the areas of application of the new computational capabilities. The software tools will be developed and released in stages so that users can start applying the technology and give feedback for future developments. What will make these tools unique is that there is no one software package that provide both easy model building capacity and the standard population kinetic methodologies: parametric, non-parametric, and two-stage. Thus the software tools will greatly enhance the overall quality of research in all types of kinetic studies. RFPK is distributed at two major universities both of whom contribute unique expertise to the project. The Administrative Core is located at the University of Washington.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Biotechnology Resource Grants (P41)
Project #
5P41RR012609-04
Application #
6363984
Study Section
Special Emphasis Panel (ZRG7-SSS-9 (07))
Program Officer
Marron, Michael T
Project Start
1998-03-24
Project End
2003-02-28
Budget Start
2001-03-01
Budget End
2002-02-28
Support Year
4
Fiscal Year
2001
Total Cost
$976,750
Indirect Cost
Name
University of Washington
Department
Biomedical Engineering
Type
Schools of Engineering
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Telford, Dawn E; Lipson, Sara M; Barrett, P Hugh R et al. (2005) A novel inhibitor of oxidosqualene:lanosterol cyclase inhibits very low-density lipoprotein apolipoprotein B100 (apoB100) production and enhances low-density lipoprotein apoB100 catabolism through marked reduction in hepatic cholesterol content. Arterioscler Thromb Vasc Biol 25:2608-14
Dash, Ranjan K; Bell, Bradley M; Kushmerick, Martin J et al. (2005) Estimating in vitro mitochondrial oxygen consumption during muscle contraction and recovery: a novel approach that accounts for diffusion. Ann Biomed Eng 33:343-55
Dodds, Michael G; Hooker, Andrew C; Vicini, Paolo (2005) Robust population pharmacokinetic experiment design. J Pharmacokinet Pharmacodyn 32:33-64
Spilker, Mary E; Seng, Kok-Yong; Yao, Amy A et al. (2005) Mixture model approach to tumor classification based on pharmacokinetic measures of tumor permeability. J Magn Reson Imaging 22:549-58
Lukas, J C; Suarez, A M; Valverde, M P et al. (2005) Time-dependent pharmacokinetics of cyclosporine (Neoral) in de novo renal transplant patients. J Clin Pharm Ther 30:549-57
Welty, Francine K; Lichtenstein, Alice H; Barrett, P Hugh R et al. (2004) Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes. Arterioscler Thromb Vasc Biol 24:1703-7
Calvo, R; Telletxea, S; Leal, N et al. (2004) Influence of formulation on propofol pharmacokinetics and pharmacodynamics in anesthetized patients. Acta Anaesthesiol Scand 48:1038-48
Tannock, L R; Little, P J; Tsoi, C et al. (2004) Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans. Diabetologia 47:837-43
Foracchia, Marco; Hooker, Andrew; Vicini, Paolo et al. (2004) POPED, a software for optimal experiment design in population kinetics. Comput Methods Programs Biomed 74:29-46
Whitfield, A J; Marais, A D; Robertson, K et al. (2003) Four novel mutations in APOB causing heterozygous and homozygous familial hypobetalipoproteinemia. Hum Mutat 22:178

Showing the most recent 10 out of 77 publications